M&A / Deals Metsera backers establish new biotech armed with China-licensed immunology asset Pharmaceutical TechnologyPHP and ARCH have established Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco.Immunology & InflammationRead full story pharminent August 26, 2026 (Last updated: September 1, 2026) Pharmaceutical Technology PHP and ARCH have established Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco. Immunology & Inflammation Read full story Post navigation Previous: Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2Next: Spyre deprioritises arthritis drug after Phase 2 results Related Stories M&A / Deals Lilly adds to immune drug pipeline with $2.9B Merida buyout pharminent August 31, 2026 M&A / Deals Acquisitive Lilly offers $2.88bn for Merida Bio pharminent August 31, 2026 M&A / Deals McKesson to acquire Precision Medicine Group for $2.25bn pharminent August 26, 2026
